Legal & General Group
RPRX

Legal & General Group’s Repros Therapeutics Inc. RPRX Stock Holding History

Legal & General Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,530
Closed -$39K – 2844
2015
Q1 		$39K Hold
4,530
– – ﹤0.01% 2599
2014
Q4 		$46K Hold
4,530
– – ﹤0.01% 2476
2014
Q3 		$46K Buy
+4,530
New +$67.1K ﹤0.01% 2445

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Legal & General Group's RPRX Position: Q2 2015 in Review

Legal & General Group sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 4,530 shares — an estimated $39K sold.

Legal & General Group first reported a position in RPRX in Q3 2014 and held it in 3 quarters. The position peaked at $46K in Q4 2014. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

  • Legal & General Group reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
  • Legal & General Group sold 4,530 Repros Therapeutics Inc. shares in Q2 2015, an estimated $39K.
  • Legal & General Group first reported a position in Repros Therapeutics Inc. in Q3 2014 and held it in 3 quarters.
  • Legal & General Group's Repros Therapeutics Inc. position peaked at $46K in Q4 2014.
  • 64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on Legal & General Group's 13F filing for Q2 2015, filed 31 Jul 2015.